Similar articles for PMID: 16144928

Year	Number of Results
1982	2
1983	1
1984	1
1985	1
1986	2
1987	3
1988	7
1989	4
1990	3
1991	8
1992	15
1993	12
1994	2
1995	9
1996	3
1997	13
1998	9
1999	13
2000	15
2001	15
2002	21
2003	22
2004	15
2005	14
2006	13
2007	15
2008	14
2009	10
2010	12
2011	15
2012	7
2013	9
2014	6
2015	8
2016	9
2017	10
2018	10
2019	8
2020	7
2021	6
2022	4
2023	3
2024	0

1

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.

Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H. Talpaz M, et al. Clin Cancer Res. 2005 Sep 1;11(17):6247-55. doi: 10.1158/1078-0432.CCR-05-0882. Clin Cancer Res. 2005. PMID: 16144928 Clinical Trial.

2

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L. Motzer RJ, et al. J Clin Oncol. 2001 Mar 1;19(5):1312-9. doi: 10.1200/JCO.2001.19.5.1312. J Clin Oncol. 2001. PMID: 11230473 Clinical Trial.

3

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.

Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Garcia-Manero G, et al. Cancer. 2003 Jun 15;97(12):3010-6. doi: 10.1002/cncr.11424. Cancer. 2003. PMID: 12784336 Free article. Clinical Trial.

4

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.

Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Kantarjian HM, et al. J Clin Oncol. 1999 Jan;17(1):284-92. doi: 10.1200/JCO.1999.17.1.284. J Clin Oncol. 1999. PMID: 10458244 Clinical Trial.

5

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S, Kantarjian HM. Talpaz M, et al. Blood. 2001 Sep 15;98(6):1708-13. doi: 10.1182/blood.v98.6.1708. Blood. 2001. PMID: 11535501 Free article. Clinical Trial.

6

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.

O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. O'Brien S, et al. Cancer. 2003 Sep 1;98(5):888-93. doi: 10.1002/cncr.11620. Cancer. 2003. PMID: 12942553 Free article. Clinical Trial.

7

Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.

Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Sacchi S, et al. Leuk Lymphoma. 1999 Nov;35(5-6):483-9. doi: 10.1080/10428199909169612. Leuk Lymphoma. 1999. PMID: 10609785 Clinical Trial.

8

Polyethylene glycol interferon-alpha2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia.

Cervantes F, Camós M, Boqué C, Besses C, Alcalá A, Sureda A. Cervantes F, et al. Haematologica. 2004 Jul;89(7):870-1. Haematologica. 2004. PMID: 15257944

9

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.

Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Kantarjian HM, et al. J Clin Oncol. 1992 May;10(5):772-8. doi: 10.1200/JCO.1992.10.5.772. J Clin Oncol. 1992. PMID: 1569449

10

Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.

Brennan BJ, Xu ZX, Grippo JF. Brennan BJ, et al. Clin Ther. 2012 Sep;34(9):1883-91. doi: 10.1016/j.clinthera.2012.07.003. Epub 2012 Aug 1. Clin Ther. 2012. PMID: 22858176 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

349 results

Results by year